EGF and non-small cell lung carcinoma: It was lately discovered that the efficacy of gefitinib was associated with EGF mutations, which is significantly more prevalent in Asian patients with NSCLC, particularly adenocarcinoma [18,19], thus explained the discrepancy in the outcome of NSCLC after gefitinib treatment.